Distinct Side Population Cell Subtypes Have Different Stemness Levels in Human Ovarian Cancer Cells

Abstract

The stemness of different side population (SP) cell subtypes in ovarian cancer cells was studied, and the heterogeneity of ovarian cancer stem cells was analyzed. The cisplatin-resistant human serous ovarian cancer cell line C13 was stained with the bisbenzimide Hoechst 33342. A flow cytometry-based fluorescence-activated sorting method was used to obtain lower-SP (LSP) cells, upper-SP (USP) cells, and non-SP cells (NSP) based on their sensitivity to the staining time and Hoechst dye concentration. The sphere-forming capability, expression levels of stem cell markers, resistance to high concentrations of cisplatin, and subcutaneous tumorigenicity in NOD/SCID mice of the different cell subtypes were evaluated. The C13 cells contained SP cells with stemness characteristics, and the LSP cell subtype expressed higher levels of stem cell markers, had higher in vitro sphere-forming capability, higher cisplatin resistance and higher in vivo subcutaneous tumorigenesis than USP cells (P<0.05). NSP cells had no stemness. In conclusion, different subtypes of ovarian cancer SP cells have different stemness levels, and ovarian cancer stem cells may be heterogeneous.

Keywords

ovarian cancer / cancer stem cells / heterogeneity / side population

References

[1] PragerBC, XieQ, BaoS. Cancer Stem Cells: The Architects of the Tumor Ecosystem. Cell Stem Cell, 2019, 24(1): 41-53

[2] VisvaderJE, LindemanGJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer, 2008, 8(10): 755-768

[3] rasetyantiPR, MedemaJP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer, 2017, 16(1): 41

[4] von FurstenbergRJ, BuczackiSJ, SmithBJ, et al.. Side population sorting separates subfractions of cycling and non-cycling intestinal stem cells. Stem Cell Res, 2014, 12(2): 364-375

[5] EunK, HamSW, KimH, et al.. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting. BMB Reports, 2017, 50(3): 117-125

[6] ZhangS, BalchC, ChanMW, et al.. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res, 2008, 68(11): 4311-4320

[7] CurleyMD, TherrienVA, CummingsCL, et al.. CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer. Stem Cells, 2009, 27(12): 2875-2883

[8] ShiMF, JiaoJ, LuWG, et al.. Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line. Cell Mol Life Sci, 2010, 67(22): 3915-3925

[9] AlveroAB, ChenR, FuHH, et al.. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle, 2009, 8(1): 158-166

[10] ChenWC, HsuHP, LiCY, et al.. Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin. Int J Oncol, 2016, 49(5): 1881-1889

[11] LiuTJ, SunBC, ZhaoXL, et al.. CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer. Oncogene, 2013, 32(5): 544-553

[12] BrabletzT, JungA, SpadernaS, et al.. Opinion: migrating cancer stem cells — an integrated concept of malignant tumour progression. Nat Rev Cancer, 2005, 5(9): 744-749

[13] GoodellMA, BroseK, ParadisG, et al.. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med, 1996, 183(4): 1797-1806

[14] ChallenGA, BolesNC, ChambersSM, et al.. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell, 2010, 6(3): 265-278

[15] SayginC, MateiD, MajetiR, et al.. Targeting Cancer Stemness in the Clinic: From Hype to Hope. Cell Stem Cell, 2019, 24(1): 25-40